Literature DB >> 6806318

Antibodies from patients with connective tissue diseases bind specific subsets of cellular RNA-protein particles.

J A Hardin, D R Rahn, C Shen, M R Lerner, S L Wolin, M D Rosa, J A Steitz.   

Abstract

We characterized the RNA-containing antigens precipitated by sera from 260 patients with positive antinuclear antibodies. 49 individuals, most of whom had systemic lupus erythematosus or Sjögren's syndrome, possessed antibodies that precipitated the previously identified RNP, Sm, Ro, and La antigens either singly or in combinations. These antigens, which are located on discrete sets of small nuclear or cytoplasmic RNA-protein particles, exhibited a number of antigenic interrelationships. One patient's serum recognized a new particle containing a small RNA which we have called Th; it also precipitated the Ro complexes. Other patients with systemic lupus erythematosus, hepatitis B virus infection, juvenile rheumatoid arthritis, myositis, and rheumatoid arthritis had antibodies that precipitated specific subsets of ribosomal RNA and transfer RNA. One patient's serum contained a monoclonal immunoglobulin G that precipitated ribosomes. Most of these antibodies identified antigenic determinants constituted at least in part of protein. The specificity of the proteins bound to particular cellular RNA, probably explains the exquisite precision with which antibodies from rheumatic disease patients discriminate among RNA subsets. Such sera should be useful probes for investigating specific roles that different RNA and RNA-protein complexes play in cellular metabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6806318      PMCID: PMC370236          DOI: 10.1172/jci110587

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Free DNA in serum and plasma from normal adults.

Authors:  C R Steinman
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

2.  Partial purification and characterization of an extractible nuclear antigen which reacts with SLE sera.

Authors:  H R Holman
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

3.  Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus.

Authors:  G Clark; M Reichlin; T B Tomasi
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

4.  Physical association of two nuclear antigens and mutual occurrence of their antibodies: the relationship of the SM and RNAprotein (MO) systems in SLE sera.

Authors:  M Mattioli; M Reichlin
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

5.  Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus.

Authors:  E M Tan
Journal:  J Lab Clin Med       Date:  1967-11

6.  Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen.

Authors:  M Mattioli; M Reichlin
Journal:  Arthritis Rheum       Date:  1974 Jul-Aug

7.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

8.  Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus.

Authors:  E M Tan; H G Kunkel
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

9.  Antibodies to cellular antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; E M Tan
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

10.  Antibodies to ribonucleic acid in systemic lupus erythematosus.

Authors:  P H Schur; M Monroe
Journal:  Proc Natl Acad Sci U S A       Date:  1969-08       Impact factor: 11.205

View more
  35 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

2.  RNA-protein interactions in the human RNase MRP ribonucleoprotein complex.

Authors:  H Pluk; H van Eenennaam; S A Rutjes; G J Pruijn; W J van Venrooij
Journal:  RNA       Date:  1999-04       Impact factor: 4.942

Review 3.  B-cell epitopes of RNA autoantigens.

Authors:  R M Hoet; W J van Venrooij
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

4.  Heterogeneous nuclear ribonucleoprotein P2 is an autoantibody target in mice deficient for Mer, Axl, and Tyro3 receptor tyrosine kinases.

Authors:  Marko Z Radic; Kinjal Shah; Wenguang Zhang; Qingxian Lu; Greg Lemke; George M Hilliard
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 5.  New RNPs of higher eukaryotes.

Authors:  J Craft; H Gold
Journal:  Mol Biol Rep       Date:  1990       Impact factor: 2.316

Review 6.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

7.  Molecular and biochemical basis for the characterisation of antinuclear and anticytoplasmic antibodies.

Authors:  L Matter
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

8.  Purification of the Sm nuclear autoantigen. Detection and clinical significance of IgM antibody.

Authors:  K M Pollard; E M Tan
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

Review 9.  Diversity and origin of rheumatologic autoantibodies.

Authors:  M J Fritzler; M Salazar
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

10.  A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen.

Authors:  Dahai Xue; Hong Shi; James D Smith; Xinguo Chen; Dennis A Noe; Tommy Cedervall; Derek D Yang; Elizabeth Eynon; Douglas E Brash; Michael Kashgarian; Richard A Flavell; Sandra L Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.